Amlodipine reduced the risk of stroke (HR < 1, 0.69-1.04) and myocardial infarction (HR < 1, 0.77-0.98) in hypertensive patients compared to active control or placebo.
Meta-Analysis
Does amlodipine reduce stroke and myocardial infarction in hypertensive patients?
Amlodipine is effective in reducing the risk of stroke and myocardial infarction in hypertensive patients.
Effect estimate: HR < 1 (95% CI 0.69-1.04)
INTRODUCTION: Hypertension is a progressive cardiovascular condition arising from complex aetiologies. Progression is strongly associated with functional and structural abnormalities that lead to multi-organ dysfunction. Stroke and myocardial infarction are two of the major complications of hypertension in India. Various anti-hypertensive drugs, such as calcium channel blockers (CCBs), beta-blockers, diuretics, angiotensin-converting enzyme inhibitors and angiotensin receptor blockers, have been the medications of choice for disease management and are known to be effective in reducing the complications of hypertension. CCBs, such as amlodipine, are also currently being used and proven to be effective, although their beneficial effects in the management of complications of hypertension like stroke and myocardial infarction (MI) have yet to be proven. Therefore, the aim of this systematic review was to evaluate the effect of amlodipine on stroke and MI in hypertensive patients. METHODS: A systematic search of English electronic databases was performed for studies with sufficient statistical power that were published between 2000 andl 30 August 2020, following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) criteria. A total of 676 papers were screened, and 13 were found eligible to be included in the meta-analysis. Studies that included patients who suffered from MI or stroke and were under amlodipine treatment were included in the analysis. The odds ratio and the risk ratio of amlodipine compared to active control/placebo were noted from the studies and statistically analyzed. RESULTS: Amlodipine had a significant effect in reducing stroke and MI in hypertensive patients. Similar to results published in reports, this systematic review proved that the hazard ratio for amlodipine was < 1 for stroke (0.69-1.04) and MI (0.77-0.98), showing that amlodipine accounted for better prevention of stroke and MI. CONCLUSION: In the pooled analysis of data from 12 randomised controlled trials and one double-blinded cohort study measuring the effect of CCBs, we found that the CCB amlodipine reduced the risk of stroke and MI in hypertensive patients. Superior results for amlodipine were found in ten of the 13 studies included in this meta-analysis.
Iyengar et al. (Sat,) conducted a meta-analysis in Hypertension. Amlodipine vs. Active control or placebo was evaluated on Stroke (HR < 1, 95% CI 0.69-1.04). Amlodipine reduced the risk of stroke (HR < 1, 0.69-1.04) and myocardial infarction (HR < 1, 0.77-0.98) in hypertensive patients compared to active control or placebo.